- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CHOP, Alemtuzumab, Plasma Samples
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 150
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- ALXN2050, Fluconazole, Rifampin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy
- Interventions
- PER977, Placebo, enoxaparin
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
- Interventions
- PF-07329640, sasanlimab, bevacizumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
- Conditions
- End Stage Renal Disease
- Interventions
- pravastatin
- Drug
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- DHP107, IV Paclitaxel
- Drug
- Lead sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more
- Conditions
- Smoking
- Interventions
- Indole-3-Carbinol, Silibinin, Silibin
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)
- Interventions
- PK-optimized oral hydroxyurea at MTD until 15 years of age.
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Acute Respiratory Failure With Hypoxia
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
- Interventions
- Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Nicotine Dependence, Tobacco Toxicity, Cardiovascular Risk Factors
- Interventions
- Standardized Research E-Cigarette (SREC), Over the Counter E-Cigarette (EC), Biological Samples, Smoking-related Questionnaires
- Other · Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-881, HYQVIA, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Pain
- Interventions
- Methadone HCl Inject 10 mg/ml (will require dilution), Methadone
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 29 Weeks to 48 Weeks
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Nicotine Dependence, Tobacco Toxicity, Nicotine Dependence, Cigarettes, Cardiovascular Risk Factor, Nicotine Withdrawal
- Interventions
- SREC
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy
- Interventions
- PF-05280014, Herceptin
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Refractory Malignancy, Advanced Malignancies
- Interventions
- PTK787/ZK222584 and Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View
- Drug · Procedure
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kettering, Ohio
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- selumetinib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more
- Conditions
- Hemophilia, Menstrual Flow Excessive
- Interventions
- Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
- Interventions
- AZD1775, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Sarasota, Florida • New York, New York + 2 more
- Conditions
- Hypoglycemia, Type 1 Diabetes
- Interventions
- Dasiglucagon
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fort Worth, Texas
- Conditions
- Renal Failure
- Interventions
- LCP Tacro (tacrolimus), Prograf
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Siltuximab, Melphalan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- Intravenous Vitamin C, Gemcitabine
- Drug
- Lead sponsor
- Jeanne Drisko, MD, CNS, FACN
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas